文献速递肺外科

新辅助治疗不增加局部晚期非小细胞肺癌袖状肺叶切除术的术后并发症发生率

Neoadjuvant therapy does not increase postoperative morbidity of sleeve lobectomy in locally advanced non-small cell lung cancer.
PubMed 文献 · J Thorac Cardiovasc Surg · 2023-03-24

该回顾性研究纳入2018年1月至2021年12月接受袖状肺叶切除术的非小细胞肺癌患者613例,其中124例接受新辅助治疗、489例未接受,经倾向性评分匹配后形成97对配对队列。匹配队列中新辅助治疗组与对照组术后并发症发生率无显著差异(25.8% vs 24.7%,P=.869)。作者结论认为新辅助治疗后袖状肺叶切除术可安全实施,不增加术后并发症。

要点

  • 匹配队列中新辅助治疗组与对照组术后并发症发生率无显著差异(25.8% vs 24.7%,P=.869)。
  • 新辅助治疗组双袖状切除比例低于对照组(3.1% vs 11.3%,P=.035),术后胸腔引流时间较对照组长(6.67±3.81 vs 5.13±3.74天,P<.001)。
  • 新辅助化疗联合免疫治疗的完全病理缓解率优于单纯化疗(28.2% vs 4.1%,P<.001),不同新辅助治疗模式的术后并发症无显著差异。

核心结论

  • 新辅助治疗后实施袖状肺叶切除术可安全进行,不增加术后并发症发生率。

研究设计与样本

  • 回顾性分析2018年1月至2021年12月接受袖状肺叶切除术的非小细胞肺癌患者,共纳入613例,其中124例接受新辅助治疗、489例未接受,采用倾向性评分匹配形成97对配对队列。

主要发现

  • 全队列单因素逻辑回归显示吸烟史(OR 1.501,95%CI 1.011-2.229,P=.044)、开胸手术(OR 1.748,95%CI 1.178-2.593,P=.006)和手术时间超过150分钟(OR 1.548,95%CI 1.029-2.328,P=.036)为术后并发症的危险因素,多因素逻辑回归显示开胸手术为独立危险因素(OR 1.765,95%CI 1.178-2.643,P=.006)。
  • 匹配队列中新辅助治疗组双袖状切除比例低于对照组(3.1% vs 11.3%,P=.035),术后胸腔引流时间较对照组长(6.67±3.81 vs 5.13±3.74天,P<.001)。
  • 匹配队列中两组术后并发症发生率无显著差异(25.8% vs 24.7%,P=.869)。
  • 化疗联合免疫治疗的完全病理缓解率优于单纯化疗(28.2% vs 4.1%,P<.001),不同新辅助治疗模式的术后并发症无显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the feasibility and safety of sleeve lobectomy after neoadjuvant therapy by assessing the postoperative morbidity. METHODS: Patients who underwent sleeve lobectomy for non-small cell lung cancer (NSCLC) were retrospectively analyzed from January 2018 to December 2021. A total of 613 patients were enrolled, including 124 patients who received previous neoadjuvant therapy and 489 patients who did not. Propensity score matching was adopted to create a balanced cohort consisting of 97 paired cases. Patient demographics and perioperative outcomes were compared between the 2 groups, and logistic regression analysis was used to identify risk factors for postoperative complications. RESULTS: In the entire cohort, univariable logistic regression analysis showed that smoking history (odds ratio [OR], 1.501; 95% confidence interval [CI], 1.011-2.229, P = .044), open thoracotomy (OR, 1.748; 95% CI, 1.178-2.593, P = .006), and operation time more than 150 minutes (OR, 1.548; 95% CI, 1.029-2.328, P = .036) were risk factors for postoperative complications, and multivariable logistic regression analysis showed open thoracotomy was an independent risk factor (OR, 1.765; 95% CI, 1.178-2.643, P = .006). In the balanced cohort, the neoadjuvant group had a lower proportion of double-sleeve resections (3.1% vs 11.3%, P = .035) and longer postoperative chest tube drainage (6.67 ± 3.81 vs 5.13 ± 3.74 days, P < .001). However, no significant differences were observed in postoperative morbidity between the 2 groups (25.8% vs 24.7%, P = .869). The complete pathologic response of chemoimmunotherapy was significantly superior to chemotherapy alone (28.2% vs 4.1%, P < .001), and no significant differences were noted in postoperative morbidity in different neoadjuvant therapy modalities. CONCLUSIONS: After neoadjuvant therapy, sleeve lobectomy can be safely performed with no increased postoperative morbidity.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Li X, Li Q, Yang F, et al. Neoadjuvant therapy does not increase postoperative morbidity of sleeve lobectomy in locally advanced non-small cell lung cancer. J Thorac Cardiovasc Surg. 2023. PMID: 36965521. doi:10.1016/j.jtcvs.2023.03.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。